FDA Extends Exelixis Drug Review to March 2027
The FDA has extended Exelixis' NDA review for zanzalintinib in combination with atezolizumab/Tecentriq for metastatic colorectal cancer by three months, moving the action date to March 3, 2027 after updated safety and efficacy data were deemed a major amendment. The development of zanzalintinib as a next-generation cancer therapy continues, with the delay potentially impacting timelines for patients, investors, and partners awaiting a decision.
Health · 10 sources · Sep 11, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Exelixis
Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.
Everything about Exelixis →- Country
- United States
- Headquarters
- South San Francisco
- Inception
- 1994
- Website
- http://www.exelixis.com